The role of osteoprotegerine in pathogenesis of mineral and bone disorders in chronic kidney disease (CKD-MBD)
Journal Title: Annales Academiae Medicae Silesiensis - Year 2014, Vol 68, Issue 4
Abstract
Mineral and bone disorders are the most common pathology in patients with chronic kidney disease (CKD) resulting in the development of accelerated atherosclerosis. Therefore, they are considered as non-traditional cardiovascular risk factors and the cause of increased morbidity and mortality, especially in patients on renal replacement therapy. Osteoprotegerin (OPG) is an important physiological regulator of osteoclastogenesis. As decoy receptor, it binds to the receptor activator of nuclear factor NF- kappaB ligand (RANKL), preventing it from binding to the (RANK) receptor and maturation of osteoclast precursors. The physiological role of OPG, beyond the regulatory function of bone turnover is the inhibition of cell apoptosis induced by inflammatory processes. Elevated levels of circulating OPG is observed in patients with severe atherosclerotic lesions. The experimental studies suggest that OPG does not stimulate, but on the contrary, inhibits the process of atherogenesis. This paper provides an overview of the available literature presenting the role of OPG in the pathogenesis of mineral and bone disorders in CKD. The results of these studies revealed the accumulation of circulating OPG in CKD patients. Additionally, OPG is rather a marker and not a factor involved in the pathogenesis of vascular calcification development in this group of patients.
Authors and Affiliations
Marzena Żelaźnicka-Wilk, Jarosław Wajda, Magdalena Olszanecka-Glinianowicz, Jerzy Chudek
Keywords
Related Articles
- EP ID EP376544
- DOI -
- Views 98
- Downloads 0
The role of VEGF-A and its receptors in angiogenesis
Angiogenesis is essential for the proper development of the organism and repair processes, but also significant in cancer progression and metastasis in solid tumors. A major cytokine that promotes the development of new...
The use of metformin in patients with chronic kidney disease
Diabetes is a disease that affects about 4% of the population, and its incidence has been growing steadily. Increasingly more young people have to face this illness, and therefore more people suffer from chronic complica...
Can laboratory parameters be predictive factors for treatment effectiveness of patients suffering from viral hepatitis C?
INTRODUCTION: The combined therapy of pegylated alpha interferon and rybavirin is a gold standard of chronic viral hepatitis C (cvhC) treatment. AIM: The aim of the study is to evaluate the laboratory test differences be...
Congenital chloride diarrhea primary treated as Bartter syndrome – case report
Congenital chloride diarrhea (CCD) is a rare autosomal recessive disease. It is caused by mutations in the SLC26A3 gene which encodes the transmembrane Cl-/HCO3- exchanger, mainly expressed in the apical epithelium of th...
Your smartphone can save someone's life
INTRODUCTION: Each year in Europe there are about 350 thousand deaths recorded, following sudden cardiac arrest (SCA). To reduce this number, new methods are being looked for to assist non-medical people in CPR. The obje...